コンテンツへスキップ
Merck

HCYTA-60K

Millipore

MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A - Immunology Multiplex Assay

別名:

Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel

ログイン組織・契約価格を表示する


About This Item

UNSPSCコード:
12161503
NACRES:
NA.84

化学種の反応性

human

品質水準

メーカー/製品名

Milliplex®

テクニック

multiplexing: suitable

入力

cell culture supernatant(s)
plasma
serum

検出方法

fluorometric (Luminex® xMAP®)

輸送温度

wet ice

保管温度

2-8°C

詳細

Cytokines, chemokines, and growth factors are key mediatorsof immune system functions capable of signaling through autocrine, paracrine,and endocrine mechanisms. Their pleiotropic immunomodulatory propertiesallow these biomolecules to react to diverse stimuli and regulate the immuneresponse, either promoting or inhibiting inflammation.

アプリケーション

  • MILLIPLEX® Qualified assays undergo rigorousassay development, verification, and Quality Control testing to achieve optimalperformance.
  • Simultaneously analyze up to 48 cytokine,chemokine, and growth factor biomarkers with bead-based multiplex assays usingLuminex technology, in human serum, plasma and cell culture samples.
  • Available analytes: sCD40L, EGF, Eotaxin, FGF-2,FLT-3L, Fractalkine, G-CSF, GM-CSF, GROα, IFNα2, IFNγ, IL-1α, IL-1β, IL-1RA,IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-15, IL-17A, IL-17E/IL-25, IL-17F, IL-18, IL-22, IL-27, IP-10,MCP-1, MCP-3, M-CSF, MDC, MIG, MIP-1α, MIP-1β, PDGF-AA, PDGF-AB/BB, RANTES,TGFα, TNFα, TNFβ, VEGF-A

特徴および利点

  • This panel is fully configurable, with options for custom bead premixing, fixed premixed and bulk premixed panels.
  • Save time and resources by simultaneously analyzing up to 48 analytes of your choice in a single sample
  • Requires a small sample volume (25 µL/well)
  • Choose same day or overnight incubation
  • Reliable and accurate performance with proven lot-to-lot consistency
  • Ready-to-use reagents
  • Comes with everything you need to run your assay
  • Includes a Serum Matrix to mimic the native sample environment in serum and plasma samples
  • Includes high and low Quality Controls

包装

96-well plate

保管および安定性

Recommended storage for kit components is 2 - 8°C.

法的情報

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

免責事項

Unless otherwise stated in our catalogor other company documentation accompanying the product(s), our products areintended for research use only and are not to be used for any other purpose,which includes but is not limited to, unauthorized commercial uses, in vitrodiagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumptionor application to humans or animals.

ピクトグラム

Health hazardCorrosionExclamation markEnvironment

シグナルワード

Danger

危険有害性の分類

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

ターゲットの組織

Respiratory Tract

保管分類コード

10 - Combustible liquids


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

HCYTA-60K-43C:
HCYTA-60K-42C:
HCYTA-60K-28C:
HCYTA-60K-38:
HCYTA-60K:
HCYTA-60K-21:
HCYTA-60K-30:
HCYTA-60K-31C:
HCYTA-60K-09:
HCYTA-60K-26:
HCYTA-60K-39C:
HCYTA-60K-13C:
HCYTA-60K-01:
HCYTA-60K-14:
HCYTA-60K-26C:
HCYTA-60K-44:
HCYTA-60K-33:
HCYTA-60K-05:
HCYTA-60K-45:
HCYTA-60K-05C:
HCYTA-60K-02C:
HCYTA-60K-04:
HCYTA-60K-48C:
HCYTA-60K-07C:
HCYTA-60K-30C:
HCYTA-60K-23C:
HCYTA-60K-32:
HCYTA-60K-19:
HCYTA-60K-24C:
HCYTA-60K-35C:
HCYTA-60K-41:
HCYTA-60K-06C:
HCYTA-60K-19C:
HCYTA-60K-36:
HCYTA-60K-35:
HCYTA-60K-42:
HCYTA-60K-34:
HCYTA-60K-39:
HCYTA-60K-16C:
HCYTA-60K-24:
HCYTA-60K-06:
HCYTA-60K-18:
HCYTA-60K-21C:
HCYTA-60K-10C:
HCYTA-60K-07:
HCYTA-60K-28:
HCYTA-60K-44C:
HCYTA-60K-16:
HCYTA-60K-11C:
HCYTA-60K-25C:
HCYTA-60K-22C:
HCYTA-60K-47:
HCYTA-60K-36C:
HCYTA-60K-17:
HCYTA-60K-18C:
HCYTA-60K-41C:
HCYTA-60K-43:
HCYTA-60K-14C:
HCYTA-60K-03:
HCYTA-60K-08:
HCYTA-60K-29:
HCYTA-60K-09C:
HCYTA-60K-04C:
HCYTA-60K-23:
HCYTA-60K-15:
HCYTA-60K-10:
HCYTA-60K-15C:
HCYTA-60K-46:
HCYTA-60K-08C:
HCYTA-60K-45C:
HCYTA-60K-13:
HCYTA-60K-40:
HCYTA-60K-32C:
HCYTA-60K-03C:
HCYTA-60K-27C:
HCYTA-60K-25:
HCYTA-60K-38C:
HCYTA-60K-12C:
HCYTA-60K-02:
HCYTA-60K-27:
HCYTA-60K-29C:
HCYTA-60K-22:
HCYTA-60K-48:
HCYTA-60K-20:
HCYTA-60K-37:
HCYTA-60K-34C:
HCYTA-60K-31:
HCYTA-60K-40C:
HCYTA-60K-12:
HCYTA-60K-46C:
HCYTA-60K-47C:
HCYTA-60K-33C:
HCYTA-60K-37C:
HCYTA-60K-20C:
HCYTA-60K-01C:
HCYTA-60K-17C:
HCYTA-60K-11:


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Myung-Ho Kim et al.
The Journal of infectious diseases (2021-05-27)
We analyzed the plasma levels of interferons and cytokines, and the expression of interferon-stimulated genes in peripheral blood mononuclear cells in COVID-19 patients with different disease severity. Mild patients exhibited transient type I interferon responses, while ICU patients had prolonged
Kelsey E Huntington et al.
eLife, 10 (2021-01-15)
Although the range of immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is variable, cytokine storm is observed in a subset of symptomatic individuals. To further understand the disease pathogenesis and, consequently, to develop an additional tool for
Jinyu Li et al.
Frontiers in immunology, 12, 749618-749618 (2021-12-11)
Increasing cases related to the pathogenicity of Enterovirus D68 (EV-D68) have made it a growing worldwide public health concern, especially due to increased severe respiratory illness and acute flaccid myelitis (AFM) in children. There are currently no vaccines or medicines
Teslin S Sandstrom et al.
Journal of virology, 95(9) (2021-02-12)
The use of unique cell surface markers to target and eradicate HIV-infected cells has been a longstanding objective of HIV-1 cure research. This approach, however, overlooks the possibility that intracellular changes present within HIV-infected cells may serve as valuable therapeutic
Liam J O'Neil et al.
Frontiers in immunology, 13, 958145-958145 (2022-09-27)
The development of autoantibody directed towards citrullinated proteins (ACPA) are predictive of RA in at-risk individuals. The biological events that underpin loss of immune tolerance and progression into inflammatory arthritis are not known. We sought to identify serum proteomic alterations

関連コンテンツ

See how multiplex assays, such as the Luminex® bead-based multiplex immunoassay MILLIPLEX® Rat Liver Injury Panel, enable researchers to simultaneously measure multiple hepatotoxic biomarkers and cytokines to expand knowledge on drug-induced liver injury processes.

イムノアッセイにロット間一貫性がないと、混乱や誤解を招く結果につながります。MILLIPLEX®マルチプレックスサイトカインアッセイが、他のLuminex®テクノロジーベースのマルチプレックスアッセイと比べて、ヒト血清および血漿サンプルのサイトカイン測定において優れたロット間一貫性を示した事例についてご覧ください。

See how MILLIPLEX® multiplex cytokine panels can be used in alternate sample types such as human tears, urine, milk, saliva, and CSF with an example of characterizing neuroinflammation across healthy, MCI, and AD CSF samples.

サイトカインマルチプレックスアッセイにより、研究者は免疫系を容易に調べることができます。MILLIPLEX®ヒトサイトカイン/ケモカイン/成長因子パネルAおよびBは、サイトカイン検出用のマルチプレックスアッセイであり、それぞれで、48種類のアナライトの特有の組み合わせを少量のサンプル量で同時に測定できます。

すべて表示

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)